Sinjen International increases revenue growth and 59% net profit in Q1

Biocon’s subsidiary Sinjen International increased its first quarter revenue by 11% in its first quarter, while net profit for this period increased by 59% to Rs. 87 crore.

A high company official attributed the continued conversion of pilot programs to a long -term contract in Pay FIRM’s research services business.

“In our biologics manufacturing division, we have seen good progress with the onset of operations in the Unit III facility in Bengaluru and the preparation of our two -faced facilities in the US,” said Peter Bens, Managing Director and CEO of Surgen International.

“We continued to strengthen and enhance our enemy .Nic platform capabilities, at the Naline brought a sophisticated, dedicated peptide laboratory. When we consider the current macroeconomic factors, we maintain a confident point of view.”

During the quarter, the company’s operating pending EBITDA margin was focused on the growth and cost of OPTIM PTIs.

“The current quarter’s PAT includes the tax gain originating from the transfer of gratuity funds Gratuity Funds,” said Deepak Jain, chief financial officer. He added, “We continue to maintain a strong balance sheet to invest in technology and capabilities to strengthen our customer’s ings furings. While keeping an eye on market trends, we are going to deliver our stated guidance for the year.”